Medication Review and Polypharmacy Assessment

Medication review and polypharmacy assessment are structured clinical processes used to evaluate the appropriateness, safety, and necessity of every drug an older adult takes. As the number of concurrent prescriptions increases, so does the risk of adverse drug reactions, dangerous interactions, and functional decline — making systematic review a core component of geriatric care. This page covers the definition and scope of polypharmacy, how formal medication reviews are conducted, the clinical scenarios that most commonly require intervention, and the decision frameworks clinicians apply when initiating or discontinuing medications.

Definition and scope

Polypharmacy is broadly defined in clinical literature as the concurrent use of 5 or more medications by a single patient, with "hyperpolypharmacy" describing regimens of 10 or more drugs (World Health Organization, Medication Safety in Polypharmacy, 2019). Adults aged 65 and older account for a disproportionate share of prescription drug use in the United States. According to the CDC National Center for Health Statistics, approximately 42% of adults aged 65 and older take 5 or more prescription medications simultaneously.

Medication review refers to a structured, critical examination of a patient's full drug regimen — including prescription drugs, over-the-counter medications, vitamins, herbals, and supplements — to identify problems such as inappropriate prescribing, duplications, underprescribing, dosing errors, and adherence issues. The Agency for Healthcare Research and Quality (AHRQ) classifies medication review as a patient safety intervention and includes it within broader quality frameworks for older adults.

Polypharmacy is not inherently pathological — a patient managing heart failure, diabetes, and hypertension simultaneously may require 7 or more medications that are each individually appropriate. The clinical challenge lies in distinguishing necessary polypharmacy from problematic polypharmacy, where drug burden exceeds clinical benefit.

The regulatory context for geriatrics in the United States includes federal requirements under the Centers for Medicare & Medicaid Services (CMS) that nursing facilities conduct medication regimen reviews for each resident at least monthly, as specified in 42 CFR § 483.45.

How it works

A structured medication review follows discrete phases:

Medication reconciliation — Compiling a complete, verified list of all substances the patient takes, cross-referencing prescribing records with patient self-report and pharmacy dispensing data to resolve discrepancies.
Clinical review — Each medication is evaluated against current diagnoses, functional status, and treatment goals using validated tools (see below).
Drug interaction screening — Automated and clinical review for pharmacokinetic and pharmacodynamic interactions, particularly relevant given age-related changes in hepatic and renal clearance.
Appropriateness assessment — Application of published criteria to flag potentially inappropriate medications (PIMs) or identify untreated conditions.
Deprescribing and optimization — Tapering, discontinuing, substituting, or dose-adjusting medications that no longer provide net benefit relative to risk.
Patient and caregiver communication — Reviewing changes with the patient and care team, updating written medication lists, and coordinating with all prescribers.

Two tools dominate clinical practice for appropriateness assessment. The Beers Criteria, maintained by the American Geriatrics Society (AGS), provides an evidence-based list of medications that are potentially inappropriate for older adults due to elevated risk relative to benefit. The most recent update (AGS Beers Criteria® 2023) categorizes PIMs across 5 domains: drugs to avoid, drugs to use with caution, drug-drug interactions, drug-disease interactions, and drugs with dosing adjustments required in renal impairment.

The STOPP/START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment), developed by a European consensus group and published in peer-reviewed literature, adds a complementary lens: STOPP identifies drugs to stop, while START identifies appropriate drugs that may be omitted (undertreated conditions). Both tools are referenced by the National Institute on Aging (NIA) and AHRQ as validated instruments for geriatric review.

For a broader clinical picture that integrates medication review with functional and cognitive assessment, the comprehensive geriatric assessment process provides the full multidomain framework within which polypharmacy review typically sits.

Common scenarios

Polypharmacy assessment is triggered by a range of clinical presentations:

Falls and fall risk — Sedatives, antihypertensives, alpha-blockers, and anticholinergics are among the drug classes most associated with fall risk in older adults. Medication review is a core component of formal fall risk assessment.
Cognitive decline or delirium — Anticholinergic burden, benzodiazepines, and opioids are implicated in acute confusion and accelerated cognitive decline. Quantifying anticholinergic load using the Anticholinergic Cognitive Burden (ACB) scale is standard practice in many geriatric programs.
Nursing home admission or care transitions — CMS-mandated monthly reviews under 42 CFR § 483.45 apply specifically to long-term care settings, where polypharmacy rates are highest.
Newly diagnosed renal or hepatic impairment — Clearance changes alter drug levels and necessitate dose recalculation or discontinuation for renally-cleared agents.
Symptom burden without clear etiology — Fatigue, appetite loss, confusion, and orthostatic hypotension are frequently medication-induced and may be misattributed to disease progression.

Strategies for reducing unnecessary medication burden are addressed in detail on the polypharmacy-reducing medications page, which covers deprescribing frameworks in clinical practice.

Decision boundaries

Not every medication flagged by Beers or STOPP criteria warrants immediate discontinuation. Clinical decision-making in polypharmacy assessment involves structured trade-off analysis:

Factors favoring continuation of a flagged medication include: documented patient-specific efficacy, absence of safer alternatives, stable long-term tolerance, patient preference aligned with informed goals of care, and short life expectancy where symptom management outweighs harm-reduction benefit.

Factors favoring discontinuation or substitution include: absence of a current active indication, drug-induced symptom burden confirmed by trial withdrawal, duplicative mechanisms within the same drug class, high ACB score contributing to cognitive or functional decline, and renal or hepatic clearance changes that render safe dosing unachievable.

The overview of geriatric care topics on this site situates medication review within the broader landscape of age-related clinical priorities including frailty, functional status, and advance care planning.

A critical classification boundary separates deprescribing (planned, supervised dose reduction or discontinuation) from medication non-adherence (unsupervised cessation). Abrupt discontinuation of beta-blockers, corticosteroids, antiepileptics, or antidepressants without clinical supervision can produce rebound effects or withdrawal syndromes. Deprescribing protocols require tapering schedules, monitoring intervals, and defined endpoints.

The managing multiple medications page addresses practical patient-level coordination strategies that support safe transitions when regimens are modified.

CMS also requires pharmacist review participation in nursing facility settings, distinguishing the institutional review process — in which a licensed pharmacist conducts the monthly medication regimen review — from the physician-led appropriateness assessment that occurs during comprehensive geriatric evaluations.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)